net dbt
result brightre row devic
revenu miss off-set oper effici
npat ahead expect bofaml con due
lower effect tax rate non-recur employe share-bas transact
highlight mask revenue cc strong growth across market support
resuppli program us gross margin improv manufactur
procur effici product mix stronger usd saa revenue
complet matrixcar acquisit full quarter impact healthcarefirst
lowlight brightre growth miss high single-digit growth compar
double-digit expect row devic cc lower sale franc
germani custom complet upgrad program
adjust estim reflect lower saa growth due brightre
oper leverag sg cost base guidanc
revenu respect
question whether success heathcarefirst matrixcar
acquisit occur short space time caus lose focu
brightre compar size matrixcar rel brightre impli saa
manag continu spread thinli pull back saa revenu growth
basi whilst expect brightre gain momentum return
doubl digit growth forecast lower end rang
remain bullish belief saa strategi benefit
long term reiter buy rate po previous share
dcf-base valuat unchang
full definit iqmethod sm measur see page
employ non-u affili mlpf registered/qualifi research analyst
finra rule
refer import disclosur inform certain bofa merril lynch entiti take
respons inform herein particular jurisdict
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
outsid equiti interest npat
chang work capit
 flow item int tax
 flow oper
oper
acquisit dispos invest
 flow invest
invest
 flow financ
financ
return capit employ
return equiti
iqmethod sm qualiti earn
full definit iqmethod sm measur see page
lead develop
manufactur medic devic mask cloud-
base softwar applic diagnos treat
manag respiratori disord headquart
san diego california focuss
connect health deliv better outcom
sleep apnea chronic obstruct pulmonari
outpac industri growth
market share place
everi market oper benefit
clinic data-captur proprietari
softwar boost therapi complianc
rate increas mask accessori growth
addit market develop
market activ target
moder sever osa suffer world-wide
price book valu
loss attribut equiti method invest
 revenue
sg revenue
tabl earn estim chang
 revenue
sg revenue
chang work cap
pv cash flow
pv termin valu
pv equiti
aud pv equiti
price object per share base dcf
valuat dcf use wacc termin growth rate
downsid risk po loss momentum saa busi market
educ effort achiev expect revenu growth reimburs
chang health ministri phi poor recept new product launch
technolog advanc competitor product fx chang
lyann harrison herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
